Abstract
Genome editing is no longer a distant promise. Patients are already being treated with CRISPR-based therapies in, among others, the United States, the United Kingdom, New Zealand, and parts of the Middle East. In Europe, despite world-class science and clinical expertise, the transition from discovery to wider clinical use remains slower, more fragmented, and less predictable than it should be. This has become my mission: to make CRISPR treatments more accessible and easier to deliver within real-world health systems.
When I first began working with genome-editing technologies more than 15 years ago, as part of the Emerging Technology at Sigma-Aldrich as a Field Application Scientist, introducing zinc finger nucleases (ZFNs) to European markets, the field’s central challenges were scientific. Could these tools function reliably? Could their applications expand? Would they ever be safe enough for clinical use?
I recall one of the earliest ZFN symposia I organized in Scandinavia, attended by approximately 70 scientists, clinicians, and students. The engagement was unquestionable. Even at that early stage, it was evident that genome editing represented a fundamentally new and promising therapeutic paradigm. Several of the early pioneers and commercial leaders in genome editing who helped shape this field are shown in Figure 1.
From lab bench to life-saving technology: early pioneers and leaders in genome editing at CRISPRMED25. (From left to right): Guillermo Montoya (University of Copenhagen); David Briner (ZFN commercialization specialist); Srinivasan Chandrasegaran (Professor Emeritus, Johns Hopkins); Jens-Ole Bock; Dana Carroll (Professor Emeritus, University of Utah Sch. Med.); T.J. Cradick (Gene Editing Frontiers); and Virginijus Šikšnys (Vilnius University, Lithuania). ZFN, zinc finger nuclease.
Patient Access
Today, as CRISPR-based therapies transition from experimental platforms to approved medicines, the primary bottleneck has shifted. The field no longer suffers from a lack of technical maturity or clinical readiness. Instead, progress is increasingly constrained by systems designed for mass-market pharmaceuticals rather than adaptive, hospital-based, one-time genomic medicines.
This shift became clear to me through direct experience. In 2017, I founded a company in the gene-editing space with a focus on safety and quality control. Years of interaction with fundamental scientists and translational researchers had made one issue unmistakable: robust detection and quantification of on- and off-target effects would determine whether genome editing could succeed clinically. COBO Technologies emerged from this insight, building on academic technology designed to address genomic fidelity and rigorous analytical validation. Without a standardized analytical infrastructure, even highly optimized CRISPR effectors face significant barriers to clinical progression and regulatory acceptance. Europe’s commitment to safety, ethics, and patient protection is rightly non-negotiable. However, when regulatory complexity becomes opaque, duplicative, or misaligned with the realities of personalized genomic medicine, it can unintentionally delay patient access without improving safety.
A similar structural gap became apparent when I launched CRISPR Medicine News (CMN) in 2019. While researchers, clinicians, regulators, investors, and patient advocates were advancing different segments of the CRISPR value chain, no dedicated community existed to integrate developments across it. It was clear to me that something was missing here that could strengthen the field, so I decided to create it, with the essential help of a handful of very talented scientific writers and editors.
During CMN’s early years, the focus was mainly on sharing the latest developments through a weekly newsletter and tracking updates from ongoing clinical trials. When stakeholders lack visibility into clinical progress, regulatory decisions, delivery technologies, and emerging safety data, translation slows regardless of scientific momentum.
Enhancing Interaction Across the CRISPR Field
The growing need to convene the global CRISPR medicine community led to the launch of the CRISPRMED conference series in Copenhagen in 2024. Instead of creating another conference focused primarily on scientific data dissemination, our ambition was to connect researchers with clinicians, industry leaders, regulators, investors, and patient advocates across the translational continuum. We saw a clear demand for structured interaction across the ecosystem
This became particularly evident at CRISPRMED25, when one of the first patients treated with CASGEVY, Jimi Olaghere, spoke about living with sickle cell disease and the impact of genome editing on his life. The response in the audience was immediate and sustained.
The discussion shifted from technical capability to clinical consequence, emphasizing both the urgency of accelerating therapeutic translation and the unresolved questions of access, especially in low- and middle-income countries. It was a clear reminder that genomic medicine is not ultimately about platforms or pipelines, but about people whose lives are shaped by the speed or slowness of our systems. The idea for a new initiative, CRISPRMED Global, grew directly from this moment, with planned partnerships and events across the Asia-Pacific region, the Middle East, Latin America, and Africa.
In recent months, I have had several conversations with hospital-based scientists across Europe who are deeply frustrated by the current system. In multiple cases, CRISPR-based treatments are scientifically validated and clinically ready, and patients with rare and ultra-rare diseases have already been identified and prepared to receive them. Yet regulatory barriers and reimbursement uncertainty are so substantial that these programs are being paused or delayed indefinitely.
At the same time, in Denmark, a number of recent documentaries have followed families with young children affected by rare genetic diseases, for whom the clock is painfully ticking. Potential treatments already exist, but access remains out of reach, either unavailable within the healthcare system or dependent on case-by-case fundraising by families to secure therapy for their child. Hearing these stories, and knowing that thousands of similar situations exist worldwide, has been almost unbearable. It made it clear to me that I needed to focus more on turning scientific breakthroughs into accessible care by innovating regulation, financing, and coordination.
These experiences have shaped my view that genomic medicine requires deliberate ecosystem construction. The European Genomic Medicine Consortium (EGMEDC), scheduled to launch in April 2026, will serve as an operational bridge to enable coordination across scientific, clinical, regulatory, industry, and funding domains.
Yet addressing the bench-to-bedside gap will require more than coordination between experts. It depends on institutional and political willingness to adapt regulatory pathways, reimbursement models, and cross-border collaboration frameworks to the realities of genomic medicine.
The Next Phase of CRISPR Medicine
The CRISPR field has attracted exceptional scientific talent and significant investment. What remains comparatively underdeveloped is the infrastructure. Data platforms capable of synthesizing global clinical outcomes, analytical services that support editing quality at scale, forums that enable sustained cross-sector dialogue, and coordination structures that facilitate efficient movement from bench to bedside are all urgently needed. Without harmonized regulatory pathways and infrastructure designed for decentralized manufacturing, reimbursement, delivery, and access, CRISPR medicine risks becoming a series of isolated technical successes rather than a broadly deployable therapeutic modality.
As genome editing expands beyond rare diseases into more prevalent conditions, these limitations will become more pronounced. Early approvals benefited from narrowly defined indications and highly concentrated resources. Treating larger patient populations across diverse therapeutic areas will require fundamentally different and more resilient supporting systems.
Scientific innovation remains essential, and those advancing CRISPR technologies deserve continued recognition. However, equal attention must be given to those building the infrastructure enabling clinical impact. While this work may lack the conceptual elegance of engineering new editors, its influence on patient outcomes is no less significant.
The next phase of CRISPR medicine will be shaped not only by technical breakthroughs, but by our collective ability to construct the systems that translate those breakthroughs into accessible therapies. EGMEDC is my commitment to building that bridge. The challenge before us is no longer whether CRISPR medicine works, but how quickly we can develop the frameworks that enable this life-saving technology to reach patients in need.